Discounted Cash Flow Rating

Buy

Return on Equity Rating

Buy

Debt to Equity Rating

Strong Buy

Price to Earnings Rating

Sell

Analyst Rating

Buy

Simple Moving Average

Strong Sell

Exponential Moving Average

Strong Sell

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Neutral

Insider Trading

Neutral

Wall Street Data Solutions Rating

Neutral

B

IQVIA Holdings Inc. (IQV)

Services-commercial Physical & Biological Research

https://www.iqvia.com

IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The Research & Development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.

2400 ELLIS ROAD
DURHAM, NC

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

05/09/2013

Market Cap

43,445,736,000

Shares Outstanding

182,500,000

Weighted SO

182,500,000

Total Employees

N/A

Upcoming Earnings

07/22/2024

Similar Tickers

SYNH --.--%

CRL --.--%

LH --.--%

MEDP --.--%

WAT --.--%

IDXX --.--%

RVTY --.--%

MTD --.--%

TWST --.--%

Beta

1.4950

Last Div

0.0000

Range

167.42-261.73

Chg

-2.5900

Avg Vol

1261241

Mkt Cap

43445736000

Exch

NYSE

Country

US

Phone

919 998 2000

DCF Diff

87.5038

DCF

151.6481

Div Yield

0.0000

P/S

2.8585

EV Multiple

16.5870

P/FV

6.4674

Div Yield %

0.0000

P/E

30.5143

PEG

3.7467

Payout

0.0000

Current Ratio

0.8492

Quick Ratio

0.8492

Cash Ratio

0.2334

DSO

79.1526

DIO

0.0000

Op Cycle

79.1526

DPO

113.1722

CCC

-34.0196

Gross Margin

0.2970

Op Margin

0.1390

Pretax Margin

0.0986

Net Margin

0.0936

Eff Tax Rate

0.0487

ROA

0.0539

ROE

0.2279

ROCE

0.1068

NI/EBT

0.9499

EBT/EBIT

0.7093

EBIT/Rev

0.1390

Debt Ratio

0.5022

D/E

1.9747

LT Debt/Cap

0.6430

Total Debt/Cap

0.6638

Int Coverage

3.0043

CF/Debt

0.1840

Equity Multi

3.9318

Rec Turnover

4.6113

Pay Turnover

3.2252

Inv Turnover

0.0000

FA Turnover

19.7904

Asset Turnover

0.5758

OCF/Share

13.3919

FCF/Share

10.0274

Cash/Share

9.2097

OCF/Sales

0.1605

FCF/OCF

0.7488

CF Coverage

0.1840

ST Coverage

2.0908

CapEx Coverage

3.9804

Div&CapEx Cov

3.9804

P/BV

6.4674

P/B

6.4674

P/S

2.8585

P/E

30.5143

P/FCF

23.7798

P/OCF

17.7959

P/CF

17.7959

PEG

3.7467

P/S

2.8585

EV Multiple

16.5870

P/FV

6.4674

DPS

0.0000

Latest Headlines (EST)

MarketWatch Dec 28, 07:46 Here's a 'solid contrarian idea' for 2024, according to BTIG's Krinsky MarketWatch Dec 28, 06:34 Here's a 'solid contrarian idea' for 2024, according to BTIG's Krinsky MarketWatch Dec 23, 07:30 Seven tech stocks that can broaden your exposure beyond the ‘Magnificent Seven’ in 2024 MarketWatch Dec 23, 07:30 Seven tech stocks that can broaden your exposure beyond the ‘Magnificent Seven’ in 2024 MarketWatch Dec 20, 12:11 Seven tech stocks that can broaden your exposure beyond the "Magnificent Seven" Investing.com Oct 31, 12:15 Earnings Coming in Better-Than-Expected, but Stocks Still Getting Punished

Revenue Product Segmentation